Baijin Life Science Holdings Limited

As of March 31, 2026, Baijin Life Science Holdings Limited carries a market capitalization of 550.03M, placing it among publicly traded companies globally. Its enterprise value stands at 542.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Baijin Life Science Holdings Limited has 932.25M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Baijin Life Science Holdings Limited maintains a current ratio of 2.97, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Baijin Life Science Holdings Limited's stock has gained approximately 195.45% over the past 52 weeks. The 50-day moving average sits at 1.34, while the 200-day moving average is 0.83.

As of March 31, 2026, Baijin Life Science Holdings Limited holds 43.11M in cash and equivalents against 28.41M in total debt, resulting in a net debt position of -29.43M. Total book value stands at 185.19M, with working capital of 127.46M providing operational flexibility.

Baijin Life Science Holdings Limited's most recent stock split took place on April 6, 2022 with a 58:61 split ratio.